#United States #Chicago #biotech #KAHR #DSP107

Exciting Developments in Colorectal Cancer Treatment

KAHR Bio, a clinical-stage biotechnology company, has recently announced an oral presentation of groundbreaking findings regarding its experimental drug DSP107. This crucial presentation will take place at the prestigious American Society of Clinical Oncology (ASCO) Annual Meeting scheduled for May 30 to June 3, 2025, in Chicago, Illinois. The research highlights the potential of DSP107, combined with the anti-PD-L1 therapy atezolizumab, to significantly improve outcomes for patients afflicted with stage three microsatellite stable metastatic colorectal cancer (MSS-CRC).

What is DSP107?

DSP107 is a pioneering bi-specific T-cell engager that activates both innate and adaptive immune responses to combat solid tumors. Unlike traditional therapies, which may often overlook specific cancer markers, DSP107 targets CD47, a protein frequently overexpressed on cancer cells that helps them evade the immune system. By binding to CD47 and converting its signals, DSP107 attracts and activates T-cells, specifically CD8 cytotoxic T-cells, initiating an effective anti-cancer response. This dual-action mechanism is particularly significant in colorectal cancer treatment, where over 70% of patients may exhibit liver metastases, complicating treatment outcomes.

Promising Results from the Phase 2 Study

The Phase 2 expansion cohort study exploring DSP107’s effectiveness was an open-label, multi-center trial that involved patients with advanced MSS-CRC who had received prior treatments. The trial aimed to evaluate the safety and tolerability of DSP107, given in conjunction with atezolizumab. The combination not only demonstrated a favorable safety profile but also elicited notable anti-tumor activity that resulted in extended survival for patients, including those with liver metastases—one of the most challenging scenarios in colorectal cancer treatment.

Yaron Pereg, CEO of KAHR, expressed enthusiasm over the opportunity to present these results at ASCO, stating: "This recognition showcases the significant potential of this immunotherapy combination to significantly benefit MSS-CRC patients, including those with challenging liver metastases, a condition with critical unmet medical needs." The oral presentation will include updated overall survival data, which has shown promising improvements beyond initial trial results.

Study Details and Presentation Information

The specifics of the presentation will be outlined as follows:

• - Title: Phase 2 dose expansion study of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, with and without atezolizumab in metastatic MSS colorectal cancer patients.
• - Session: Gastrointestinal Cancer—Colorectal and Anal
• - Date: June 1, 2025
• - Time: 11:30 AM - 1:00 PM CDT
• - Presenter: Anwaar Saeed, MD, Associate Professor of Medicine at the University of Pittsburgh Medical Center.

Future Implications for Colorectal Cancer Treatment

The implications of this study could be transformative for the treatment landscape of MSS-CRC, particularly as current therapies yield limited success. Colorectal cancer, especially in its MSS form, typically demonstrates resistance to immunotherapy due to its lower mutational burden and lack of immune infiltrate. However, DSP107’s innovative approach offers hope for enhancing immune cell responses within tumors, addressing a critical gap in effective treatment options for colorectal cancer.

As KAHR moves forward, the data shared at ASCO could pave the way for potential regulatory approvals and broader adoption of DSP107 in various cancer treatment protocols. Colorectal cancer remains a leading cause of cancer-related death worldwide, and advancements in therapies like DSP107 could significantly alter prognosis for patients seeking effective treatment.

For anyone interested in the evolving narrative of cancer treatment, the findings from KAHR Bio at ASCO 2025 undoubtedly mark an exciting chapter worth following closely.